Audentes Therapeutics Inc (NASDAQ:BOLD)’s share price fell 1.3% on Thursday . The company traded as low as $19.62 and last traded at $23.91. 14,740 shares traded hands during trading, a decline of 98% from the average session volume of 758,339 shares. The stock had previously closed at $24.23.
A number of brokerages have weighed in on BOLD. Raymond James reiterated a “hold” rating on shares of Audentes Therapeutics in a research report on Wednesday. B. Riley increased their target price on shares of Audentes Therapeutics from $20.00 to $21.00 and gave the stock a “sell” rating in a research report on Wednesday. HC Wainwright set a $33.00 price target on shares of Audentes Therapeutics and gave the stock a “buy” rating in a report on Wednesday. William Blair downgraded shares of Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. Finally, Mizuho reissued a “buy” rating and issued a $45.00 price target on shares of Audentes Therapeutics in a report on Wednesday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. Audentes Therapeutics has a consensus rating of “Hold” and a consensus price target of $36.00.
The firm has a market capitalization of $904.48 million, a PE ratio of -7.06 and a beta of 1.99.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.09). During the same period in the previous year, the firm earned ($0.88) EPS. As a group, sell-side analysts expect that Audentes Therapeutics Inc will post -3.39 EPS for the current fiscal year.
In related news, CEO Matthew R. Patterson sold 12,952 shares of the firm’s stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $40.00, for a total value of $518,080.00. Following the sale, the chief executive officer now directly owns 12,952 shares of the company’s stock, valued at $518,080. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $36.88, for a total transaction of $368,800.00. Following the completion of the sale, the vice president now directly owns 100 shares in the company, valued at $3,688. The disclosure for this sale can be found here. Insiders sold 77,039 shares of company stock worth $2,925,260 over the last ninety days. 6.60% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in BOLD. Partner Investment Management L.P. purchased a new position in shares of Audentes Therapeutics during the second quarter worth approximately $162,000. Cubist Systematic Strategies LLC purchased a new position in shares of Audentes Therapeutics during the first quarter worth approximately $204,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Audentes Therapeutics during the second quarter worth approximately $226,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Audentes Therapeutics during the second quarter worth approximately $231,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Audentes Therapeutics during the second quarter worth approximately $232,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This article was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/11/10/audentes-therapeutics-bold-shares-down-1-3.html.
Audentes Therapeutics Company Profile (NASDAQ:BOLD)
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: Short Selling Stocks and Day Traders
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.